Ionis Pharmaceuticals discontinued development of a candidate intended to prevent Alzheimer’s disease in people with Down syndrome, the company confirmed following reporting by Endpoints. Ionis said the decision reflects internal program assessment and strategic reprioritization. The termination removes one of several targeted efforts addressing high Alzheimer risk in Down syndrome and underscores the development challenges in this niche patient population. The company did not provide detailed trial data in the announcement; stakeholders will watch for whether the decision reflects efficacy, safety, or portfolio refocusing.